R-GASTIM- Study of Gastric Cancer Operable
NCT07787052 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-08-26
Summary
Clinicobiological cohort of gastric cancers operated in our institution.
Conditions
Sponsors & Collaborators
-
Centre Leon Berard
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2027-09-30
- Completion
- 2027-09-30
Countries
- France
Study Locations
More Related Trials
-
Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
NCT01483014 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
NCT01323400 ·Status: COMPLETED ·Phase: PHASE2
-
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
NCT00290485 ·Status: UNKNOWN ·Phase: PHASE2
-
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
NCT00171977 ·Status: COMPLETED ·Phase: PHASE4
-
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
NCT00867113 ·Status: COMPLETED ·Phase: PHASE2
-
Gastrointestinal Stromal Tumors (GIST) Registry
NCT00507273 ·Status: COMPLETED
-
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
NCT03963544 ·Status: COMPLETED
-
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
NCT00135005 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance
NCT00367861 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
NCT00278876 ·Status: COMPLETED ·Phase: PHASE2
-
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
NCT00812240 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Nilotinib Versus Imatinib in GIST Patients
NCT00785785 ·Status: COMPLETED ·Phase: PHASE3
-
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
NCT05132738 ·Status: UNKNOWN ·Phase: NA
-
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
NCT02260505 ·Status: COMPLETED ·Phase: PHASE3
-
A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
NCT01839500 ·Status: COMPLETED
-
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
NCT05009927 ·Status: RECRUITING ·Phase: PHASE2
-
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
NCT04193553 ·Status: COMPLETED ·Phase: PHASE2
-
Sarcopenia in Patients With Gastrointestinal Stromal Tumours
NCT02877368 ·Status: COMPLETED
-
Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
NCT03381053 ·Status: UNKNOWN
-
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
NCT00293124 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
NCT00877045 ·Status: COMPLETED
-
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
NCT01172548 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
NCT00137449 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Surival of GIST Patients ≥ 10 Years on Imatinib
NCT04097093 ·Status: WITHDRAWN
-
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
NCT01646593 ·Status: NO_LONGER_AVAILABLE